Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.76 |
| ▸ | HPGD | P15428 | 4/20 | 0.76 |
| ▸ | MAPT | P10636 | 4/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25440183 | 0.86 | MAPT (0.78) | KMT2AHPGDMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL25440072 | 0.86 | KMT2A (1.00) | KMT2AHPGDMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2027720 | 0.85 | MAPT (1.00) | KMT2AHPGDMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL25440184 | 0.84 | KMT2A (0.74) | KMT2AHPGDMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL25440173 | 0.79 | HPGD (0.69) | KMT2AHPGDMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL31197024 | 0.78 | KMT2A (0.53) | KMT2AHPGDMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL25440265 | 0.77 | KMT2A (0.65) | KMT2AHPGDMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10795656 | 0.74 | ALDH1A1 (0.57) | KMT2AHPGDMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6942981 | 0.72 | MAPT (0.60) | KMT2AMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL18235442 | 0.72 | STAT3 (0.47) | KMT2AHPGDMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382840-A1 | ANTI-INFLAMMATORY COMPOUNDS | AMAR SALOMON (US) | 2023-11-30 | — | — | US | claimed |
| US-20230382840-A1 | ANTI-INFLAMMATORY COMPOUNDS | AMAR SALOMON (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382840-A1 | ANTI-INFLAMMATORY COMPOUNDS | AMAR SALOMON (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382840-A1 | ANTI-INFLAMMATORY COMPOUNDS | AMAR SALOMON (US) | 2023-11-30 | — | — | US | disclosed |
| US-11767283-B2 | Anti-inflammatory compounds | AMAR SALOMON (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767283-B2 | Anti-inflammatory compounds | AMAR SALOMON (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767283-B2 | Anti-inflammatory compounds | AMAR SALOMON (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382840-A1 | ANTI-INFLAMMATORY COMPOUNDS | TNF, IL1A, NFKBIA | KMT2A 786/4885HPGD 343/4885MAPT 4746/4885 |
| US-11767283-B2 | Anti-inflammatory compounds | TNF, IL1A, NFKBIA | KMT2A 815/4885HPGD 342/4885MAPT 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.